Clinical trial
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache
NCT00123201 is registered in ClinicalTrials.gov with Solvay Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache
- Lead sponsor
- Solvay Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2005
- Completion date
- March 31, 2007
- Enrollment
- Not reported
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.